In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 32, No. 3_suppl ( 2014-01-20), p. 466-466
Abstract:
466 Background: MARS is a prospective multicentric study conducted to assess the renovascular tolerance of anti-VEGF drugs (AVD) in the clinical setting in France, in a number of different tumor types. Methods: Patients (pts) from 8 centers were included when they were 1) naive of any AVD and 2) about to start treatment with an AVD, from 2009 to 2012, with a follow-up (f/u) of 1 year. Data collected included: gender, age, serum creatinine (SCr), HTN, hematuria (Hu) and dipstick Pu, at baseline and at each visit during f/u. This subgroup analysis presents the results for colorectal cancer (CRC) pts receiving bevacizumab (BVZ). Results: 1,124 pts were included. 200 had CRC and all but 5 received BVZ. Median age: 63.2 years. Visceral, bone, and cerebral metastasis frequencies were 91.3, 10.8, and 0.5%, respectively. All pts presented metastasis. At inclusion, HTN prevalence was 26.2%. Baseline renal assessment retrieved: Pu 30.6%, Hu 10.1%, mean aMDRD 91.1 ml/min/1.73m 2 . The incidence of de novo Pu and HTN during f/u was 78.2 and 16.1% (Table). 75.6% of pts with Pu at inclusion improved or remained stable. Among pts with de novo Pu, 60.8% afterward improved/normalized. No grade 4 Pu has been reported (at inclusion or during f/u). Renal function decreased with a mean aMDRD of 90.3 at the end of f/u. 5.9% had grade 2 SCr increase (no grade 3-4). No thrombotic micro-angiopathy (TMA) was reported. Conclusions: These results on the renovascular safety of BVZ in CC patients showed that 1) TMA is rare, 2) Pu develops in 78.2% of the pts (no grade 4), 3) 16.1% developed HTN. Furthermore, in case of a renovascular effect, investigators followed the recommendations from the French Society of Nephrology (Halimi JM. Nephrol Ther 2008) and no treatment withdrawal for unmanageable renovascular toxicity occurred. [Table: see text]
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2014.32.3_suppl.466
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2014
detail.hit.zdb_id:
2005181-5
detail.hit.zdb_id:
604914-X
